Evolocumab (AMG 145) is a human monoclonal antibody specifically designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is extensively utilized in research focused on hypercholesterolemia and atherosclerotic cardiovascular disease due to its unique mechanism of action. Evolocumab effectively binds to the circulating PCSK9 protein, preventing its interaction with the low-density lipoprotein receptor (LDLR), thereby facilitating the maintenance of LDLR levels on hepatocyte surfaces and promoting LDL clearance.
Additionally, Evolocumab exhibits antioxidant and cytoprotective properties, offering protection against H₂O₂-induced oxidative damage in endothelial cells. This is particularly relevant in studies exploring endothelial function under oxidative stress conditions. Furthermore, preliminary evidence suggests that Evolocumab may inhibit the activation of the TLR-4/NF-κB signaling pathway, potentially reducing inflammatory responses, which is crucial in the context of cardiovascular diseases. This multifaceted biological activity makes Evolocumab a valuable tool in cardiovascular research, particularly in the investigation of mechanisms underlying lipid metabolism and inflammation.
Evolocumab (AMG 145) is a human monoclonal antibody specifically designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is extensively utilized in research focused on hypercholesterolemia and atherosclerotic cardiovascular disease due to its unique mechanism of action. Evolocumab effectively binds to the circulating PCSK9 protein, preventing its interaction with the low-density lipoprotein receptor (LDLR), thereby facilitating the maintenance of LDLR levels on hepatocyte surfaces and promoting LDL clearance.
Additionally, Evolocumab exhibits antioxidant and cytoprotective properties, offering protection against H₂O₂-induced oxidative damage in endothelial cells. This is particularly relevant in studies exploring endothelial function under oxidative stress conditions. Furthermore, preliminary evidence suggests that Evolocumab may inhibit the activation of the TLR-4/NF-κB signaling pathway, potentially reducing inflammatory responses, which is crucial in the context of cardiovascular diseases. This multifaceted biological activity makes Evolocumab a valuable tool in cardiovascular research, particularly in the investigation of mechanisms underlying lipid metabolism and inflammation.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
